

Special Issue

Advances in the Treatment of Gastrointestinal (GI) Cancers

Message from the Guest Editor

This Special Issue aims to present recent advances in the treatment of gastrointestinal (GI) cancers, including esophageal, gastric, colorectal, pancreatic, and hepatobiliary malignancies. We welcome original research articles and reviews focusing on novel therapeutic strategies, biomarker-driven approaches, immunotherapy, targeted therapy, and emerging molecular mechanisms underlying GI tumor progression and resistance. Studies addressing translational research, clinical trials, and precision oncology are particularly encouraged. Through this Collection, we seek to provide a platform for sharing cutting-edge findings that can contribute to improved outcomes and personalized treatment approaches in GI oncology.

Guest Editor

Dr. Yoshiyasu Kono

Department of Gastroenterology and Hepatology, Okayama University Hospital, Okayama 700-8558, Japan

Deadline for manuscript submissions

27 February 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/236979

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)